New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
09:05 EDTCYTXCytori Therapeutics 7.02M share Spot Secondary priced at $2.85
Lazard Capital acted as sole book running manager for the offering.
News For CYTX From The Last 14 Days
Check below for free stories on CYTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
09:07 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTCYTXBARDA executes contract option with Cytori valued at $12.1M
Subscribe for More Information
August 18, 2014
13:31 EDTCYTXCytori Therapeutics appoints Girao CFO to replace Saad
Subscribe for More Information
August 12, 2014
11:20 EDTCYTXCytori Therapeutics reports publication of six month data from scleroderma study
Cytori Therapeutics (NASDAQ: CYTX) today announced that six month outcomes from a 12 patient independent investigator-initiated study using Cytori Cell Therapy to treat scleroderma have been published in the Annals of Rheumatic Disease. Data from the study indicated that treatment with Cytori Cell Therapy was safe and well tolerated through six months. In addition, the data indicated an approximately 50% average improvement across four key, validated endpoints used to assess the clinical status in patients with systemic scleroderma with impaired hand function at two months, with benefits sustained through six month follow-up. “After six month follow up, we are encouraged by the results that have been seen by the investigators in France...The investigators in Marseille have continued to follow the patients and are considering a larger, controlled study based on these positive outcomes,” said Dr. Steven Kesten, Chief Medical Officer, Cytori.
August 11, 2014
16:21 EDTCYTXCytori Therapeutics announces departure of CFO Mark Saad
Cytori Therapeutics announced that Mark Saad, its CFO, has accepted a new opportunity and will be officially leaving Cytori, effective today. It added, "Cytori has recruited a highly qualified candidate who is extremely familiar with Cytori and is currently employed at a local medical company to be our next CFO and VP Finance. The Company will provide a further update on the CFO candidate, who is anticipated to start in September, on the investor call this afternoon." The board has appointed Dr. Marc Hedrick, Cytori’s CEO, to serve as Principal Financial Officer until a new CFO is appointed.
16:19 EDTCYTXCytori Therapeutics reports Q2 EPS (15c), consensus (13c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use